Author Title Type [ Year(Asc)]
Filters: Author is Rocha, Vanderson  [Clear All Filters]
Barban JBernardo, Simões BPinto, Moraes BDel Guerra, da Anunciação CRehem, da Rocha CSantos, Pintor DCristina Q, Guerra DCristina, Silva DAndrade, Brandão Ede Castro, Kerbauy F, et al. Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults. Einstein (Sao Paulo). 2020;18:AE4530.
Buzo BFernando, Ramos JFernandes, Rossetti RAriza Marq, Salles N, Medrone-Júnior A, Rocha V, Nastri ACatharina. Hepatitis B virus among hematopoietic stem cell transplant recipients: antiviral impact in seroconversion, engraftment and mortality in a Latin American center. Transpl Infect Dis. 2020:e13243.
Arcuri LJavier, Nabhan SKanaan, Cunha R, Nichele S, Ribeiro AAlice Feit, Fernandes JFolloni, Daudt LEsteves, Rodrigues ALuiza Melo, Arrais-Rodrigues C, Seber A, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after Haploidentical donor hematopoietic stem cell transplantation with post-transplant cyclophosphamide for relapsed/refractory severe aplastic anemia: Haploidentical HCT with PTCy for SAA. Biol Blood Marrow Transplant. 2020.
Fernandes JFolloni, Nichele S, Arcuri LJavier, Ribeiro L, Netto GZamperlini, Loth G, Rodrigues ALuiza Melo, Kuwahara C, Koliski A, Trennepohl J, et al. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biol Blood Marrow Transplant. 2020.
Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, Sierra J, Michallet M, Saccardi R, Rocha V, et al. Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020.
da Silva WFernandes, da Rosa LInês, Seguro FSalles, Silveira DRafaele Al, Bendit I, Buccheri V, Velloso EDeolinda R, Rocha V, Rego EM. Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics (Sao Paulo). 2020;75:e1566.
Piñana JLuis, Xhaard A, Tridello G, Passweg J, Kozijn A, Polverelli N, Heras I, Pérez A, Sanz J, Berghuis D, et al. Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2020.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Balassa K, Danby R, Rocha V. Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med (Lond). 2019;80(1):33-39.
Flor-Park MV, Kelly S, Preiss L, Custer B, Carneiro-Proietti ABF, Araujo AS, Loureiro P, Maximo C, Rodrigues DOW, Mota RA, et al. Identification and characterization of hematopoietic stem cell transplant candidates in a sickle cell disease cohort. Biol Blood Marrow Transplant. 2019.
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transplant. 2019.
Balassa K, Salisbury R, Watson E, Lubowiecki M, Tseu B, Maouche N, Jeffery K, Misbah SA, Benamore R, Rowley L, et al. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation. J Infect. 2019.